• Introduction: Index Funds are Eating Speculative Soup
  • An Easy Win for Active Managers?
  • But is Biotech so Different This Time?: Maybe Not!
  • Conclusion: The Frightful Cost of Buying Scratch Tickets in Two Charts
  • Appendix: Fundamentals
  • Exhibit

Introduction: Index Funds are Eating Speculative Soup

In the most recent paper Index Rebalancing and the Passive Patsies Kailash Concepts focused on the mechanical disadvantage inherent during index rebalancing due to its historical bias towards the addition of abnormally expensive and speculative assets. Kailash believes this has never been more relevant than today due to the elevated valuations of recent and potential additions approaching levels last seen at the peak of the dot com bubble. To summarize our prior work since December: passive investors may be ill served as a looming wall of exorbitantly priced unicorns may become eligible for index inclusion in the months and years ahead. As Kailash has shown in prior work,1 history has brutally punished index inclusions with these characteristics.

Having combed through the listing of recent additions to the R2500 index, not only were these additions trading at record P/S multiples but nearly half could not register a multiple due to an absence of revenues. This has led to an increase in overall index constituents with zero revenues as shown in Fig. 1 below. Since 2017 the percent of firms in the R2500 with zero revenues has more than doubled and is now at an all-time record. As the following research shows, regardless of the recent biotech sector bias, firms with zero revenues have historically offered investors dismal batting averages and terrible returns. It seems the primary appeal to these stocks is akin to buying a lottery ticket rather than an investment.

icons8 vertical line 50
icons8 lock 50


The information, data, analyses, and opinions presented herein (a) do not constitute investment advice, (b) are provided solely for informational purposes and therefore are not, individually or collectively, an offer to buy or sell a security, (c) are not warranted to be correct, complete or accurate, and (d) are subject to change without notice. Kailash Capital, LLC and its affiliates (collectively, “Kailash Capital”) shall not be responsible for any trading decisions, damages or other losses resulting from, or related to, the information, data, analyses or opinions or their use. The information herein may not be reproduced or retransmitted in any manner without the prior written consent of Kailash Capital. In preparing the information, data, analyses, and opinions presented herein, Kailash Capital has obtained data, statistics, and information from sources it believes to be reliable. Kailash Capital, however, does not perform an audit or seeks independent verification of any of the data, statistics, and information it receives. Kailash Capital and its affiliates do not provide tax, legal, or accounting advice. This material has been prepared for informational purposes only and is not intended to provide, and should not be relied on for tax, legal, or accounting advice. You should consult your tax, legal, and accounting advisors before engaging in any transaction. © 2021 Kailash Capital, LLC – All rights reserved.

Nothing herein shall limit or restrict the right of affiliates of Kailash Capital, LLC to perform investment management or advisory services for any other persons or entities. Furthermore, nothing herein shall limit or restrict affiliates of Kailash Capital, LLC from buying, selling or trading securities or other investments for their own accounts or for the accounts of their clients. Affiliates of Kailash Capital, LLC may at any time have, acquire, increase, decrease or dispose of the securities or other investments referenced in this publication. Kailash Capital, LLC shall have no obligation to recommend securities or investments in this publication as result of its affiliates’ investment activities for their own accounts or for the accounts of their clients.